Exelixis (NASDAQ:EXEL) Given “Equal Weight” Rating at Stephens

Stephens reiterated their equal weight rating on shares of Exelixis (NASDAQ:EXEL) in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has a $29.00 target price on the biotechnology company’s stock.

A number of other analysts have also issued reports on EXEL. Wells Fargo & Company raised their target price on shares of Exelixis from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Stifel Nicolaus raised their price objective on Exelixis from $26.00 to $30.00 and gave the stock a “hold” rating in a report on Wednesday, October 16th. Guggenheim reiterated a “buy” rating and issued a $42.00 target price on shares of Exelixis in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Exelixis in a research note on Monday, January 27th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $41.00 price objective on shares of Exelixis in a research note on Thursday, January 23rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.00.

Exelixis Stock Down 0.0 %

NASDAQ EXEL opened at $32.80 on Wednesday. The stock has a market cap of $9.37 billion, a price-to-earnings ratio of 21.03, a price-to-earnings-growth ratio of 0.63 and a beta of 0.53. Exelixis has a fifty-two week low of $20.14 and a fifty-two week high of $37.59. The business has a fifty day moving average of $34.24 and a 200-day moving average of $30.72.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 22.43% and a return on equity of 20.99%. As a group, analysts anticipate that Exelixis will post 1.74 EPS for the current year.

Insider Transactions at Exelixis

In other news, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the sale, the executive vice president now directly owns 486,059 shares of the company’s stock, valued at approximately $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Patrick J. Haley sold 41,588 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $34.36, for a total value of $1,428,963.68. Following the completion of the transaction, the executive vice president now owns 288,665 shares in the company, valued at approximately $9,918,529.40. This trade represents a 12.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 111,588 shares of company stock valued at $3,981,864 over the last quarter. Company insiders own 2.85% of the company’s stock.

Institutional Investors Weigh In On Exelixis

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Principal Securities Inc. boosted its stake in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares during the last quarter. USA Financial Formulas bought a new stake in shares of Exelixis in the fourth quarter worth $32,000. V Square Quantitative Management LLC acquired a new stake in Exelixis in the third quarter valued at $30,000. Kestra Investment Management LLC bought a new position in Exelixis during the 4th quarter valued at $39,000. Finally, UMB Bank n.a. boosted its stake in Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 553 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.